我們已在上線！進一步了解

Aurinia Pharmaceuticals

AUPH

市值 US$22億

16.51 USD

-0.22

1.32%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

16.50

-0.01

0.06%

1天

-1.32%

5天

-0.6%

1個月

-2.65%

3個月

3.58%

6個月

4.3%

今年迄今

7.56%

1年

42.94%

5年

-16.19%

10年

278.67%

關於： Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

員工： 128

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 62.5%

中性 37.5%

負面 0%

Zacks Investment Research

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Settles Patent Litigation with Teva

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Zacks Investment Research

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS Growth

Healthcare stocks have outperformed in the past month amid a rotation away from the AI trade and other risk-on investments. Global fund managers increased positions in healthcare more than any other sector or asset, according to Bank of America's July survey. In volatile markets, investors tend to pivot to defensive sectors, and healthcare has been a top performer during periods of uncertainty, including ahead of November's U.S. midterm elections.

Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS Growth

Playing The Biotech Breakout With Insiders

Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.

Playing The Biotech Breakout With Insiders

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study's primary endpoint is the proportion of patients achieving complete renal response (CRR).

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Zacks Investment Research

Aurinia (AUPH) Upgraded to Strong Buy: Here's Why

Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Aurinia (AUPH) Upgraded to Strong Buy: Here's Why

查看新聞排名

價格圖表採用Lightweight Charts™實作